Continuance of life
J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca’s Tagrisso
Continuance of life, Combined, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Overall Survival, Tagrisso
J&J and Legend’s Carvykti Demonstrates Significant Survival Benefit in Earlier-Line Multiple Myeloma Treatment
Carvykti, multiple myeloma, CAR-T therapy, Johnson & Johnson, Legend Biotech, CARTITUDE-4, survival benefit, second-line treatment
AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefit in Muscle-Invasive Bladder Cancer, Raises Questions on FDA Approval for Perioperative Design
AstraZeneca, Imfinzi, durvalumab, muscle-invasive bladder cancer, MIBC, perioperative trial design, FDA approval, survival benefit
WCLC24: Rybrevant-Lazcluze Combination Shows Enhanced Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC
Rybrevant, Lazcluze, Tagrisso, EGFR-mutated NSCLC, MARIPOSA study, WCLC24, survival benefit, first-line treatment.
AstraZeneca’s Calquence Achieves Significant Progression-Free Survival in Phase III CLL Trial, Eyes Fixed-Duration Approval
AstraZeneca, Calquence, Phase III CLL Trial, Fixed-Duration Approval, Chronic Lymphocytic Leukemia, Progression-Free Survival
AstraZeneca and Daiichi Sankyo’s TROP2 ADC Demonstrates Clinically Meaningful Survival Improvement in Phase 3 Lung Cancer Subgroup
AstraZeneca, Daiichi Sankyo, TROP2 ADC, Datopotamab Deruxtecan, Lung Cancer, Phase 3 Trial, Survival Improvement, Nonsquamous Non-Small Cell Lung Cancer
Bristol Myers’ Opdivo fails part two of post-kidney cancer surgery test as competitor Merck touts new survival data
Bristol, Myers, Opdivo, post-kidney cancer surgery test, Continuance of life